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Abstract
Ehlers Danlos Syndrome is a group of heritable loose connective tissue disorders with 13
distinguished subtypes. The hypermobile type of Ehlers Danlos Syndrome (hEDS) is the most
common subtype and is caused by a genetic mutation that leads to defective collagen fibrils. This
leads to joint instability and hypermobility, skin elasticity, widespread pain, fatigue, and
generalized tissue fragility. Chronic pain is reported to be a symptom in as high as 92% of the
hEDS population (Voermans et al., 2010); despite this prevalence, there is a significant lack of
research, awareness, and treatment standardization regarding pain in hEDS. This literature
review aims to investigate the mechanisms of pain hypothesized to be the root of increased pain
prevalence in hEDS patients, provide an overview of additional factors that contribute to pain in
hEDS, as well as to investigate the efficacies of the therapies which are most often suggested for
pain management in these patients. This review covers the three main suggested sources of pain
in hEDS: musculoskeletal trauma, central sensitization, and neuropathy. Based on research
findings, it is probable that all three of these pain mechanisms play a role in the manifestation of
chronic pain in hEDS patients. Fatigue, proprioception and balance deficits, kinesiophobia,
depression and anxiety, and deconditioning are additional factors that contribute to the
progression of chronic pain. Therapies found to be most successful in hEDS patients in the
treatment include targeted physical therapy, myofascial trigger point injections, opioids,
ketamine, and medicinal marijuana, with surgery proving to be an effective treatment in limited
scenarios. Despite this list of effective treatments, survey studies suggest that those who seek
professional treatment present with more complaints of functional impairment in their daily lives
than those who do not (Rombaut et al., 2011). This highlights the need for further research

2

surrounding effective treatments as well as a standardized treatment guide for physicians treating
patients with hEDS.
Introduction
Ehlers Danlos Syndrome is a heritable, loose connective tissue disorder that contains 13
subtypes, all sharing variable symptoms which result from abnormalities in the collagen structure
(Castori, 2012). The most common of the subtypes is Hypermobility Type (hEDS). The clinical
manifestation of hEDS includes joint hypermobility, tissue fragility, widespread pain, fatigue,
skin hyperelasticity, and other highly variable symptoms such as gastrointestinal problems and
mental illness (Mao and Bristow, 2001). The exact prevalence of this disease in the world
population is suspected to be at about 1 in 5,000 people for all subtypes combined, with about
80-90% of these cases being accounted for by hEDS (Tinkle et al., 2017). However, there is very
limited research to support this finding as EDS is a highly neglected disease in the medical field,
with the lack of education and awareness on behalf of medical professionals playing the main
role. Therefore, it is suspected that this incidence is much higher than reported.
Chronic pain has been reported to be a highly variable, yet common, manifestation of
hEDS. Although this is a common symptom experienced by hEDS patients, the direct cause(s) of
the pain is a part of a continued debate. The most logical reason for chronic pain related to hEDS
would be due to injuries resulting from the lack of collagen structure. However, two main
theories suggest that there is likely another mechanism that is involved in the development of
chronic pain in hEDS patients. The first theory is central sensitization, meaning that the central
nervous system is hypersensitive to sensory input. The second theory is neuropathy, which
defines nerve damage. In this review of literature, I aim to place my focus on studies that closely
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investigate the proposed mechanisms of pain in hEDS patients and provide an overview of
emerging therapeutic interventions shown to be successful through clinical studies. The goal of
this literature review is to gain a deeper understanding of the origin of pain in hEDS and how to
recognize this in patients to work towards a more developed, standardized treatment guide for
chronic pain in hEDS in healthcare.
Disease Background
Disease History and Clinical Description
In the first decade of the 1900s, Edvard Ehlers and Henri Danlos became the first people
to document and describe the hypermobility and elasticity of the skin and joints that are most
notable in those with EDS (Gensemer et al., 2020). In the year of 1946, “Ehlers-Danlos
Syndrome” became the name of this mysterious disease, with the subtypes being distinguished in
the late 1960s. These subtypes were documented in the Berlin nosology at this time, with the
Villefranche nosology following in 1998. Most recently, EDS was more concisely defined by the
EDS International Consortium in 2017 in which 13 subtypes of EDS were classified and of
which diagnostic criteria were assigned.
Ehlers Danlos Syndrome Hypermobility Type is hypothesized to be caused by a mutation
in one or more genes that is related to collagen structure and integrity. The exact genetic defect
related to this subtype is unknown, though there have been suggestions of specific genes in past
literature (Castori, 2012). HEDS is thought to be an autosomal dominant heritable disease with a
50% chance of being passed down to children. Although this rate of heritability does not depend
on the sex of the child, hEDS tends to have a higher incidence among females. This skewed ratio
suggests that the disease is most often transmitted by the mother and may be defined as a genetic
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trait with incomplete penetrance (Castori, 2012). This means that despite the trait having the
ability to be passed down to male children, they may have a higher chance of being “carriers” of
the disease. Thus, there seems to be an increased chance of the female fetus developing the
disease in the womb when compared to the male fetus. Additional literature suggests the reason
behind this phenomenon to be that females are naturally more flexible and have less muscle tone,
leaving them more susceptible to developing this disease to a higher degree of severity
(Gensemer et al., 2020). A difference has been noted in past studies in the development of hEDS
in boys and girls during puberty (Tinkle and Levy, 2019). In this study, boys and girls scored the
same regarding joint hypermobility before going through puberty. Following puberty, the joint
hypermobility scores of boys decreased while those of the females increased. This suggests that
pubescent hormones play a role in the development of joint laxity. It has also been suggested that
females are more often diagnosed with this disorder as they have been noted to be more likely to
seek medical attention when it is required than men (Gensemer et al., 2020). Therefore, this
incidence of hEDS in females versus males may be skewed for various reasons.
Collagen is found throughout the entire body, including in tendons, joints, fascia, and the
skin. Thus, the defective collagen fibrils can cause widespread symptoms that become difficult to
manage. The most notable manifestation of hEDS in patients is joint laxity. Joint hypermobility
refers to the hypermobility of joints that increases the patient’s susceptibility to soft tissue injury.
Joint hypermobility in hEDS most commonly leads to the hyperextension of joints such as the
knee and elbow, the subluxation and dislocation of joints, sprains, soft-tissue lesions, increased
muscle tension, and widespread musculoskeletal pain (Castori, 2012; Tinkle and Levy, 2019). In
addition to joint hypermobility, other typical manifestations of hEDS are skin fragility, organ
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prolapse, fatigue, headaches, anxiety, depression, gastrointestinal dysfunction, and kinesiophobia
(Castori et al., 2010). The clinical manifestation of hEDS is highly variable from patient to
patient, therefore these symptoms should not be generalized for the entire population of hEDS
patients.
There are three phases recognized by geneticist Marco Castori in which hEDS naturally
progresses (Castori et al., 2010). The first phase is labeled as the hypermobility phase in which
the patient can contort their body and perform what is known as “party tricks” using their joint
laxity. It is common for these children to partake in sports where their joint hypermobility is
celebrated, such as dance or gymnastics. Pain is not common in this phase, though it does have
the ability to begin during this period. The second phase is known as the pain phase which begins
in the second decade of the patient’s life. Throughout the progression of this phase, the
hypermobility of the patient decreases as their joint and muscle pain increases. During this
period, the dislocations and subluxations experienced during the first phase may become
frequent and debilitating. Finally, the last phase is known as the stiffness phase. This phase is
normally entered later in life in one’s 50s or 60s, and chronic pain is often observed in this phase
as well. This phase is characterized by the gradual stiffening of joints and a change in the
vertebral curvature, and it is noted that anxiety and depression are common.
Diagnosis
Genetic testing is available for all subtypes of Ehlers Danlos syndrome except the
hypermobility subtype. This is the only subtype that lacks a genetic marker; therefore, its
diagnosis must be made purely based on a clinical evaluation. In 2017, the diagnostic criteria
were redefined for hEDS by the EDS International Consortium. Since 1998, the diagnostic
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criteria have been outlined by the Villefranche nosology, which was done so poorly according to
researchers (Tinkle and Levy, 2019). Prior to this refinement, a system known as the Beighton
scoring system was the only diagnostic tool used for this disease. The Beighton scoring system
was developed in 1973 as a diagnostic tool for generalized joint hypermobility (Tinkle et al.,
2017). This scoring system requires five out of nine points to be scored for the diagnosis of EDS
to proceed. The system involves the measurement of the hyperextensibility of five different
joints. One point is scored for each joint that is considered hypermobile by the system’s
standards; these joints include both little fingers, thumbs, knees, elbows, and the trunk (Tinkle
and Levy, 2019). This is considered a valuable diagnostic tool as it holds the advantage of being
able to be done in-office, it is concise, and it tests a limited number of joints.
Since the redefining of EDS by the EDS International Consortium, the diagnostic criteria
for hEDS have become much more specific and rigorous and may require further refining in the
future. As outlined by the EDS International Consortium, three criteria must be met by the
patient for a clinical diagnosis of hEDS to proceed (Tinkle and Levy, 2019). The first criterion is
a positive Beighton score. The second criterion requires that at least two of the three outlined
features must be present in the patient. Feature A contains a list of common symptoms seen
among those with a generalized connective tissue disorder, and five of these must be present in
the patient to meet the criteria. Feature B refers to the presence of a positive family history of
hEDS. Feature C requires that at least one of the three listed musculoskeletal complications is
present in the patient. Finally, the third criterion requires that three exclusion criteria be met to
rule out other diseases.
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Misdiagnosis and medical wandering are common issues among hEDS patients,
indicating the need for increased awareness and education among medical professionals. Based
on feedback from the EDS community, there is a high amount of skepticism present in the
medical community regarding the legitimacy of their disease despite its debilitating
characteristics (Scheper et al., 2015). HEDS is most often misdiagnosed as fibromyalgia due to
the consistent presentation of widespread pain, weakness, and fatigue (Benistan and Martinez,
2019). A survey published in 2010 reported that out of 16 major rare diseases, EDS had the
longest diagnostic delay (Castori et al., 2010). This same survey reported that patients with EDS
consulted with up to 20 specialists before finally receiving an accurate diagnosis. This is a major
issue for those affected by this disease as this may have detrimental effects on the quality of life
of the patient. A delayed diagnosis results in wasted time and money, leaving the patients
vulnerable to wrong therapies, the worsening of the disease and mental state, and excessive
expenses. Therefore, further research on this disease must be published in order to increase
awareness among medical professionals to ensure that a proper and timely diagnosis is possible
for all EDS patients.

Joints tested in the Beighton scoring system (Tinkle and Levy, 2019).
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Treatment
As of today, there are no official guidelines regarding the treatment of hEDS. Therefore,
treatment plans for hEDS patients typically involve the management of individual symptoms to
improve the quality of life of patients through interventions such as medication and physical
therapy (Gensemer et al., 2020). Physical therapy is considered to be the most crucial of the
suggested therapeutic interventions as the physical therapist is capable of creating a highly
specific treatment plan and implementing manual therapy (Reychler et al., 2021). Because Ehlers
Danlos Syndrome-Hypermobility Type is such a variable disease that manifests itself differently
in every patient, its treatment should be highly individualized for each patient with the focus
being to minimize the burden of each symptom experienced.
Chronic Pain in hEDS
Prevalence
As defined by Merriam Webster’s medical dictionary (2021), pain is a bodily sensation
that is the result of naked nerve endings transmitting the signal related to the painful signal tied
to tissue damage to the spinal cord, resulting in physical discomfort. When chronic, pain can be
debilitating and has a major negative effect on the quality of life of a person. Although chronic
pain has been documented to be the most frequent manifestation of hEDS, it remains a highly
neglected symptom of hEDS by medical professionals (Kalisch et al., 2019). According to this
same source, misdiagnosis of fibromyalgia is frequent among these patients with a documented
rate of about 42%. Kalisch et al. (2019) report that joint and muscle pain prevalence among
hEDS patients reaches up to 90-100%. Despite this high incidence of chronic pain among hEDS
patients, there is a lack of standardized recognition and treatment of pain following a diagnosis
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of this disease. Pain symptoms and their severity have often been reported by these patients to be
underestimated or dismissed entirely by physicians (Benistan and Martinez, 2019). The opioid
epidemic has also certainly affected the treatment of pain patients, leading to the increase of
disbelief among physicians towards patients seeking pain management. This problem only
highlights the need for further pain research regarding hEDS and a standardized guideline for
pain management specific to this disease.
Source of Pain in hEDS
Due to the lack of research in this field, the exact mechanism behind chronic pain in
hEDS is a topic of ongoing debate. Several factors influence the severity, location, and type of
pain that is experienced by the hEDS patient. However, the main factors that will be covered in
this paper are biomechanical, neurological, psychosocial, and factors of physical fitness. These
factors have been reported in literature to be the major determinants of chronic pain in hEDS
(Scheper et al., 2015). The reason and physiology behind the neurological component of the
chronic pain experienced in hEDS have yet to be agreed upon as a research community;
however, there are promising studies that have been published in recent years that indicate that a
more consistent explanation regarding the pain pathology of this disease will be available in the
near future. This would allow clinicians to better recognize chronic pain in hEDS and allow them
to create a better treatment plan based on their educated distinction of the type of pain being
experienced.

10

Biomechanical Factors Influencing Pain in hEDS
Joint Instability and Musculoskeletal Trauma
Joint instability is the most common and widely recognized manifestation of
Hypermobile-Ehlers Danlos Syndrome. This joint instability, as previously described, is caused
by a presumed genetic mutation that causes defective collagen to be present in the body (Tinkle
et al., 2017). Collagen is found in many areas of the body that are involved in maintaining the
structure of the musculoskeletal system. This defective collagen then leads to the reduced
stability of joints, ligaments, and tendons. When there is a deficit of structural integrity in the
body, this increases the risk of injury and also requires an unnatural compensation mechanism to
be put into place to restore stability, causing a number of negative musculoskeletal consequences
(Scheper et al., 2015).
There are two broad types of pain regarding the nervous system: the first is nociceptive,
which means that pain pathways are being activated at a higher rate than normal. The one
seemingly obvious source of heightened nociceptive activity would be musculoskeletal trauma.
Hyperelasticity in hEDS leaves patients vulnerable to soft tissue damage (Voermans et al., 2010)
and leads to microtraumas on joint surfaces (Scheper et al., 2015). These microtraumas result in
an increase in nociceptive activity as expected, which then leads the patient to compensate for
the painful joint. This compensation may be conscious or subconscious. Subconscious
compensation involves the muscles straining to maintain stability amidst the loss of joint
function. Conscious compensation involves adjusting certain movements or postures to relieve
pressure placed on the damaged joint, which places a more intense load on these other areas of
the musculoskeletal system. These compensation mechanisms place additional strain on the
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musculoskeletal system and intensify the nociceptive activities of the nervous system that are
already heightened due to the injured joint. Although this is a simple answer to a complex
question, the way that pain manifests itself in hEDS patients cannot be explained by this
mechanism alone.

Hypermobile joints in patients with hEDS (Castori et al., 2012).

Proprioception and Balance
Decreased proprioception has been noted within the hEDS community. Proprioception is
defined as the ability to understand where your body is in space (Merriam-Webster, 2021). In the
early stages of disease progression, poor balance and proprioception may be noted, with patients
being described as “clumsy” in children and even adults. Poor balance and decreased reflexes in
the knee extensors have been documented in hEDS patients and are linked to decreased activity
levels (Engelbert et al., 2017). According to this same source, decreased joint proprioception has
a major influence on the association between muscle strength and activity limitations. Reduced
proprioceptive acuity leaves the patient more vulnerable to injury as it heightens their chances of
making movements that are beyond what they intended on performing, ultimately increasing
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pain levels (Scheper et al., 2015). Proprioceptors in the joints are thought to be damaged in
hEDS patients as a direct result of the joint hypermobility, damaging and stretching the nerves
beyond their limits (Engelbert, 2017). Balance, proprioception, and reflexes are extremely
important for safe and painless mobility, and their deficits in hEDS patients contribute to
increased musculoskeletal pain and atrophy as well as activity limitations among these
individuals.
Neurological Factors
Central Sensitization
A mechanism of pain that has been hypothesized to be the root of chronic pain symptoms
in hEDS is known as central sensitization. This refers to the overactivity of nociceptive pathways
within the patient’s central nervous system. One study performed by Kawasaki et al. (2008)
showed that pro-inflammatory cytokines (PICs) contribute to sensitization. These are proteins
that are responsible for the upregulation of inflammatory responses in the body. It has been
hypothesized from previous studies that PICs are induced in glial cells following injury to the
nerves and subsequent inflammation. As we know, injury and microtraumas are common with
this disease, therefore there is likely to be higher PIC activity in hEDS individuals than in
healthy individuals. Following their induction, this study suggests that the PICs work to suppress
inhibitory neurotransmission and enhance excitatory neurotransmission. The suppression of
inhibitory neurotransmission is known as disinhibition. The PICs mentioned in the article were
found to be responsible for the transcription of the protein CREB, which may be the main
contributor to long-lasting pain sensitivity. This hypothesis is supported by the findings of Leone
et al. (2020) in which the participants of their study were found to have a reduction in
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endogenous pain inhibitory control, also known as disinhibition. This signifies that participants
felt a more intense pain following a “conditioning” stimulus, rather than feeling less intense pain.
This inability to control nociceptive input following repeated stimuli is hypothesized to lead to
central sensitization.
In a study published in 2016 (Di Stefano et al.), it was found that central sensitization
may very well be a component of the chronic pain that those with hEDS experience. This study
used quantitative sensory testing to measure pain severity in various areas of the body which
showed that hEDS sufferers experience chronic, widespread pain similarly to those with
fibromyalgia. The study participants also experienced hyperalgesia to hot and cold stimuli as
well as an increased wind-up ratio. A wind-up ratio regarding pain is defined as an increased
pain response after undergoing a repeated painful stimulus (Di Stefano et al., 2016). This finding
is supported by that of Benistan and Martinez (2019) in which an increased wind-up ratio was
present in 37% of patients following the application of heat and cold stimulus on painful joints.
These two results from the 2016 study are major indicators of central sensitization as the main
mechanism in hEDS pain.
Di Stefano et al. (2016) argue that the diagnosis for neuropathic pain requires an
indication that the somatosensory nervous system has undergone some form of damage, and that
this study did not prove this to be true in hEDS patients. This study utilized a questionnaire that
is a very specific survey for neuropathic pain, known as the DN4 survey. Along with this
questionnaire, objective tests that tested somatosensory nerve damage included a motor and
sensory nerve conduction study involving superficial electrodes placed along major nerves in the
body. Laser-evoked potentials were also studied in participants using laser beams to elicit
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pin-prick sensations to the participant’s hands and feet to determine the lowest threshold at which
they could perceive 50 percent of the stimuli. Despite the conclusions from prior studies, the
participant responses to the DN4 questionnaire indicated that neuropathic pain was not the cause
of the widespread pain experienced by EDS patients. The nerve conduction study also failed to
support the hypothesis that there is somatic sensory nerve damage present in Ehlers Danlos
Syndrome patients. The authors believe that the reason for the discrepancy in results is due to
variation in the methods used to diagnose neuropathic pain.
The results of this study that support the hypothesis of central sensitization as the main
mechanism behind the pain experienced by EDS sufferers include the heat and cold stimuli
threshold and wind-up ratio results. These results demonstrate that the participants had a
heightened pain sensitivity to heat and cold and that the pain lasted for a longer period after the
stimulus was removed when compared to healthy participants. The other result that indicates that
central sensitization plays a role in chronic pain is the reported widespread pain experienced by
patients. This symptom was reported through the completion of the fibromyalgia rapid screening
tool. The authors hypothesize that the chronic pain experienced by EDS patients has an
underlying mechanism like that of fibromyalgia. According to the authors, these are all major
indications that central sensitization is the main underlying mechanism in chronic pain among
hEDS patients and that neuropathy is not present among these patients.
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Examples of pain diagrams from the study by Di Stefano et al. (2016).

A separate study published in 2014 by Rombaut et al. presents subsequent data to support
the hypothesis that central sensitization plays a role in chronic pain in hEDS, in addition to
neuropathic pain. In this study, 23 females with hEDS underwent an assessment to measure pain
pressure thresholds. The participants of this study tested with pain thresholds that were
significantly lower than those of the healthy control group. The pain pressure thresholds were
tested on various areas of the body, and all areas, excluding the right calf, resulted in a lower
threshold for hEDS participants. The pain thresholds also proved to be lower even at
asymptomatic areas of the body. The participants were also asked to fill out a pain diagram along
with a questionnaire designed to test for neuropathic pain, known as the Pain Vigilance and
Awareness Questionnaire. The questionnaire provided split results, indicating that about half of
the participants suffer from mainly neuropathic pain, and the other half suffer from mainly
nociceptive pain due to central sensitization The pain diagrams submitted by the participants
showed a significant difference in the amount of pain felt on the body between the control and
hEDS groups. The diagrams of the hEDS participants covered a mean of 31% of the body
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surface, while the diagrams of the healthy controls covered a mean of 1% of the body surface.
This widespread pain felt by hEDS participants, along with the lowered pain thresholds even at
asymptomatic sites, allowed the authors to conclude that central sensitization plays a role in
chronic pain in this disease.
Neuropathic Pain
An additional hypothesis that aims to explain the underlying mechanism of pain in hEDS
patients is neuropathy, which is the second type of broad pain regarding the nervous system.
Neuropathic pain is caused by damaged nerves that are responsible for transmitting information
from your peripheral to your central nervous system (Merriam-Webster, 2021). According to
Castori and Voermans (2014), it is thought that the frequent dislocations, subluxations, and
general joint laxity places abnormal pressure on peripheral nerves, leading to their damage. It is
hypothesized by Kawasaki et al. (2008) that damaged nerves create an imbalance between the
inhibitory and excitatory synaptic actions within the dorsal horn neurons in the spinal cord. This,
in turn, is thought to cause neuropathic pain by enhancing excitatory synaptic transmission while
also inhibiting inhibitory synaptic transmission, known as disinhibition. As a result, nociceptive
pathways are enhanced through excitation without inhibitory control. This has been explained in
research to be the cause of central sensitization as well, so it is likely that these two forms of pain
are not mutually exclusive. As mentioned previously, Di Stefano et al. (2016) did not find
evidence for the presence of neuropathy in hEDS patients. However, several other researchers
have published articles that contradict these findings.
It has often been found in studies researching neuropathic pain incidence in hEDS
patients that approximately half of the participants are likely to suffer from neuropathic pain
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based on validated surveys for diagnosing neuropathic pain (Rombaut, 2014; Camerota, 2011).
Although these surveys are deemed to be a highly specific tool for this diagnosis, additional
methods have since been utilized to make this determination.
A study supporting the presence of neuropathic pain in hEDS patients came to this
conclusion by obtaining skin biopsies from the participants (Cazzato et al., 2016). 100% of these
skin biopsies showed a significant decrease in intraepidermal nerve fiber density. This means that
the nerve fibers found within the epidermis in hEDS patients were found to be less dense in the
skin than in control patients. This indicates the degeneration of the nerve fibers, which is,
therefore, an indication of small fiber neuropathy. To support this finding, 95% of these
participants were indicated to have neuropathic pain according to the DN4 questionnaire. It is
unknown whether or not the loss in the density of these nerve fibers is directly related to the
cause of neuropathic pain or is simply a marker of small fiber neuropathy.
Benistan and Martinez et al. (2019) completed a study in which they researched the
source of pain in hEDS patients using vibratory and quantitative sensory testing, as well as
surveying. This study not only proves that neuropathic pain is present in hEDS patients using the
DN4 questionnaire but also suggests the incidence of neuropathic pain as a result of the
quantitative sensory testing. The sensory testing used in the study involved the application of
heat and cold stimuli to determine pain thresholds. Hypoesthesia, or the loss of feeling, was
found in participants following heat stimulus. This finding is suggestive of small fiber
neuropathy in these participants. Additionally, the DN4 questionnaire found that 75% of
participants suffered from neuropathic pain. From these results, we can assume that small fiber

18

neuropathy does play a role in the development of chronic pain in hEDS patients with
neuropathic pain being present in such a majority of the samples.
Psychosocial Factors
Depression and Anxiety
Psychological conditions among hEDS patients are all but rare. The most common
conditions are anxiety and depression and are most frequent in the late-second and third stages of
the disease (Castori et al., 2010). In one retrospective study completed by Hershenfeld et al.
(2015), 42.5% of a sample of patients with classic and hypermobility type EDS patients were
found to suffer from a psychiatric condition, with 22% of these patients suffering from more than
one condition. This is a much higher rate than what is found among the normal population,
which is estimated by the National Institute of Mental Health to be about one in five adults in the
United States (2020). This is suggested to reflect the decreased quality of life that results from
the comorbidities of hEDS and their contribution to the decline of hEDS patients in the later
stages of the disease (Baeza-Velasco et al., 2018).

Graph depicting the higher prevalence of psychiatric disorders among hEDS patients (Hershenfeld et al., 2015).
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Fatigue
Fatigue is an extremely common complaint among the hEDS community, taking place as
the most common neurologic complaint alongside chronic pain (Castori, 2012). Much like
chronic pain, fatigue is very poorly characterized within the scope of this disease as its pathology
remains largely unknown (Cetelli et al., 2021). This symptom usually coincides with the increase
in pain levels in the second phase of the disease. The diagnosis of chronic fatigue is also
commonplace among hEDS patients (Tinkle et al., 2017). Fatigue is considered to be chronic
when it lasts longer than six months consistently. In a study conducted by Voermans et al. (2010),
31% of the functional impairment reported by hEDS patients was caused by pain and fatigue
together, with fatigue being the leading cause of impairment between the two. Fatigue most
certainly contributes to the overall decline and pain chronicity of hEDS patients through their
disease progression but remains another neglected symptom of the disease.
Kinesiophobia
Kinesiophobia has been found to affect a large portion of those affected by hEDS and is a
direct result of the pain and fatigue associated with this disease. Kinesiophobia is defined as the
fear of movement or reinjury (Celleti et al., 2021). Chronic fatigue is a common comorbidity of
chronic pain in hEDS; this level of fatigue can be highly debilitating and is suggested to play a
role in the decline of hEDS patients throughout the second phase of the disease. It is
controversial whether fatigue plays a causal role in the eventual mental and physical decline of
hEDS patients or if it is a symptom that is a result of the patient's decline (Hershenfeld et al.,
2015); regardless, fatigue is considered to be a crucial factor in the development of
kinesiophobia (Scheper et al., 2015).
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In one study published by Celleti et al. (2021), 93% of patients surveyed scored at a level
that was highly suggestive of the presence of kinesiophobia. It was found in this study that there
is a correlation between the presence of pain and kinesiophobia, but not the severity of pain.
Instead, the severity of fatigue was found to have a significant correlation with kinesiophobia in
hEDS patients. These findings suggest that kinesiophobia is more directly related to the coping
mechanisms of the patient based on their fatigue and the presence of pain rather than the severity
of the pain itself.
Factors of Physical Fitness
Deconditioning
Scheper et al. (2015) describe the effects of kinesiophobia as a cycle rather than just
another symptom of hEDS. In the case that the patient experiences a new pain, this newfound
fear of this pain will lead to the avoidance of the contracting of the related muscles. This, in turn,
leads to muscle performance which is less than what is considered maximal contraction for that
person. As described previously, muscle performance is vital to maintaining joint stability in
those with joint hypermobility through the compensation mechanisms it provides. With
decreased muscle tone, these compensation mechanisms are not as effective, leaving the patient
more vulnerable to injury, which then results in more pain.
This loss of muscle tone is known as deconditioning (Baeza-Velasco et al., 2018).
Deconditioning may not only lead to an increased perception of pain, but also an increased level
of mental and physical fatigue (Tinkle and Levy, 2017). Deconditioning of the musculature of the
patient leaves the individual more vulnerable to injury, worsening of mental illness, and
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increased intensity of kinesiophobia. This cycle can be crippling and once it has advanced, it is
very difficult to escape from.

A depiction of the chronic pain cycle (Scheper et al., 2015).

Cardiovascular Function
One direct result of deconditioning is reduced cardiovascular functioning. This is
hypothesized to contribute to the orthostatic intolerance that appears to be prevalent among
hEDS patients (Hershenfeld et al., 2015). Orthostatic intolerance refers to the inability to
maintain stable blood pressure when changing from a seated or lying position to an upright or
standing position. According to Kalisch et al. (2019), pain is aggravated as a direct result of the
decrease in cardiovascular functioning, known as cardiovascular dysautonomia. Cardiovascular
dysautonomia is known to increase fatigue as well, contributing to the vicious cycle of
deconditioning, kinesiophobia, and pain. In order to penetrate and halt this cycle, action must be
taken early in its making. Early therapeutic intervention is crucial to maintaining muscle tone
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and cardiovascular function in the patient, allowing for the maximal quality of life to be
accomplished.
Therapeutic Interventions
As discussed in the introduction to this paper, there is no formal guideline for pain
management or therapy for hEDS patients. In the absence of official treatment guidelines, it is
encouraged that hEDS patients receive highly individualized treatment plans intending to
minimize the burden of each symptom. HEDS manifests itself very differently in each patient,
therefore it is difficult for researchers to generalize a treatment plan for all affected individuals.
However, there are suggestions of various treatments supported by studies published by
researchers that have shown to ameliorate major symptoms shared among the majority of hEDS
patients. Although it is impossible to cover every single type of therapy available, therapies
stemming from three broad categories will be discussed: physical therapy, medicinal therapy, and
surgical intervention. These are the therapies that are most commonly used for the treatment of
hEDS patients and have been seen to have the most success in improving the quality of life of
these individuals.
Physical Therapy
The most common form of therapy that is prescribed for hEDS patients is physical
therapy. It is also thought to be the most effective form of therapy for this population, though
there is a lack of research evidence to compare various treatment efficacies for this patient group.
In a study conducted by Demes et al. (2020), 60.6% of participants rated their experience in
physical therapy as moderately to extremely helpful, with 89% of the entire study group having
participated in physical therapy at some point before the study.
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As described in the overview of the disease, hEDS patients suffer from a wide variety of
debilitating symptoms that make it very difficult to maintain muscle tone and therefore maintain
joint stability. There are two very common physiotherapy paths that therapists normally follow
when treating hEDS patients: a general physical therapy program aimed at increasing overall
muscle strength, and a targeted program aimed to correct the motion control of the affected
joints. A study performed by Kemp et al. (2009) compared the two routes of physical therapy for
children suffering from joint hypermobility symptoms in regard to their effectiveness in reducing
pain. The study found that targeted physiotherapy appeared to be the most beneficial overall.
However, the children assessed for this study all experienced significant improvements in their
pain scores, regardless of the form of physical therapy that was administered over time.
The general physical therapy program that was administered for this study involved a set
of exercises that were geared towards increasing overall fitness and muscle strength. These
exercises included squat thrusts, sitting-to-standing, jumping jacks, and shuttle runs. As the study
progressed, new exercises were added, and the difficulties were increased. The targeted
physiotherapy program administered for this study aimed to increase the functional stability of
the symptomatic joints by retraining the muscles involved in motion control. The steps involved
in this form of physiotherapy include identifying the neutral resting position of the symptomatic
joint, maintaining these postural muscles while moving an adjacent joint and while active, and
muscle stretching. Through these steps, it is the goal to instill these postural corrections in the
patient’s muscle memory using proprioceptive techniques. The results of this study indicate that
both forms of physiotherapy are effective forms of treatment in hEDS patients, with targeted
physiotherapy suggested to be more effective in reducing pain scores.
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A separate study completed by Celleti et al. (2021) took this approach to physiotherapy
even further, labeling it as a neurocognitive form of therapy. This form of therapy involved
guided felt sense, which is a process by which the participant “rewired” the way that they
perceived their pain. The goal of this form of therapy was to better learn how to control the
elements of their daily movement as well as enhance and alter their perception of pain to gain a
better understanding of their pain and its source. The results of this study showed very significant
improvement in the participants’ pain, fatigue, disability associated with pain, and kinesiophobia.

Therapy techniques utilized in neurocognitive physical therapy (Celleti et al., 2021).

Another study performed by Ferrell et al. (2004) focused on the proprioceptive aspects of
physical therapy by aiming to increase the stimulation of Ruffini nerve endings. These nerve
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endings are known to be slow-adapting and contribute to proprioception (Merriam-Webster,
2021). The exercises in this study were designed to specifically stimulate these nerve endings in
the knee joint, which involved repeated pressure on the symptomatic joint via closed-kinetic
chain exercises. These are exercises that you may do standing in one position, including squats,
planks, etc. These exercises were chosen as they not only improve proprioception but also place
less strain on the joints and focus on recruiting multiple muscles to contract at once, overall
improving joint stability. The participants in this study experienced a significant improvement in
muscle tone, proprioception, balance, and pain scales.
Physical therapy tends to be the first choice for therapeutic intervention, and for good
reason. Joint instability is often met with muscle tension to compensate for the laxity. Muscle
tone must be maintained to prevent deconditioning, which allows comorbidities such as chronic
fatigue and depression to have an increased influence on the patient’s quality of life. Physical
therapy also allows for a highly specific treatment plan to be created with manual therapy being
implemented when necessary (Reychler et al., 2021). Although physical therapy is an excellent
option for treatment for hEDS, this may not always be enough to lessen the burden of all the
symptoms of this disease for some patients. In this case, procedural intervention may be
required.
Procedural Interventions
Procedural intervention refers to any type of intervention that requires a specific
procedure performed by a physician. One procedural intervention that has been shown to be
effective in hEDS patients suffering from musculoskeletal pain is myofascial trigger point
injections. The myofascia is known as the soft tissue that surrounds the muscle. If there is stress
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or damage done to the muscle, such as excessive muscle tension as a result of joint laxity, trigger
points, also known as knots, develop and become painful (Tewari et al., 2016; Castori et al.,
2015). These painful myofascial trigger points may be treated with trigger point injections,
which are typically a combination of a local anesthetic, saline, and/or a corticosteroid (Hammi et
al., 2021). In one case study conducted by Tewari et al. (2016), a 30-year-old female with hED
presented with chronic back pain and was administered two trigger point injections. Instructions
to administer heat therapy, massage, stretches, and NSAIDs for a week following the injections
were given by the physician. This patient reported 60-80% pain relief after one week following
treatment. By the end of the second week, the pain had reduced by half of the prior week’s pain
score. The patient reported being mostly pain-free for the following eight months.
The physiology of myofascial trigger points is not well understood, yet they are reported
to occur in 30-93% of all people suffering from pain (Tewari et al., 2016). This treatment is a
relatively non-invasive, simple procedure that is suggestive of long-lasting results when
combined with physical therapy. HEDS patients are vulnerable to myofascial trigger points as
their compensation mechanism for their joint laxity is increased muscle tension to induce
stability. Thus, the use of myofascial trigger point injections in hEDS patients suffering from
chronic musculoskeletal pain would likely prove to be effective in reducing pain in the patient
while holding the advantage of avoiding an invasive or time-consuming procedure.
Another common procedural intervention considered for the treatment of hEDS is
surgery. Surgery is often thought to be a “quick fix” for musculoskeletal issues by some;
however, due to the slowed wound healing and joint laxity that is seen in hEDS, surgical
intervention often worsens the patient’s quality of life in many ways (Gensemer et al., 2020). In
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one study conducted by Rombaut et al. (2011), survey results showed that patients with hEDS
who did receive surgical treatment at some point in time had a higher level of functional
impairment than those who did not. Despite this finding, 70.9% of patients in the study had
undergone surgical treatment, with most being completed on a major joint such as the knee,
shoulder, etc. Only 33.9% of these patients reported that the surgical intervention was successful,
indicating that it had a positive effect on their symptoms. Therefore, surgical intervention must
be considered with caution when treating an hEDS patient as it is suggestive of being a “last
resort” method of treatment for this population. If it is decided to be utilized as a method of pain
relief, extra precautions are suggested to be taken, such as gentle force during dissection,
minimal tension used for suturing, and the use of steri-strips and additional layers of sutures to
avoid the reopening of the wound (Tinkle et al., 2017).
Medicine
In a survey conducted by Demes et al. (2020), the therapies used by hEDS patients were
recorded as well as their feedback about each therapy. The medicinal therapies found to be most
efficacious according to the patients were opioids and various forms of marijuana. In this study,
opioids were reported to be moderately to extremely helpful in 88.1% of the patients who used
them as a treatment for their chronic pain. Opioids have been reported to be the most effective at
higher pain levels than at lower pain levels in hEDS patients, where NSAIDs have been reported
to be more efficacious. In this same study conducted by Demes et al. (2020), opioids were being
used as pain management among 70% of the study cohort. The rate of opioid usage, according to
this same source, is suspected to be at about 34% for the general population. Despite this
increase in opioid usage in hEDS patients, a study conducted by Rombaut et al. (2011) reported
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that patients who used opioids for pain management had a significantly higher number of
complaints of functional impairment than those who did not. This result indicates that those
using opioid medication to treat their pain related to hEDS experienced a higher level of
dysfunction in their lives. Thus, opioid medication may be effective at treating a high degree of
pain, but it may come at the cost of functional impairment in hEDS patients as well as a slew of
unwanted side effects and a high risk of addiction with long-term use.
The second medicinal therapy that was suggested to be the most effective according to a
survey of hEDS patients is different forms of marijuana (Demes et al., 2020). These forms of
marijuana, rated least effective to most effective, included marijuana concentrate, topical
marijuana, edible marijuana, vaporized marijuana, marijuana tinctures, and smoking marijuana,
with the last two forms having the same self-reported efficacies. It was reported that marijuana
was used when experiencing higher pain levels, which may indicate a preference for marijuana
use with more severe chronic pain. Marijuana preference among this population may be
explained by the simultaneous management of anxiety that this treatment option offers, as
anxiety surrounding pain is prevalent in hEDS patients.
A case report of an 18-year-old female with hEDS is consistent with these findings as
well as prior research surrounding chronic pain and marijuana use (Dar, 2021). This patient
experienced chronic pain as a result of an unsuccessful surgery aimed to treat her TMJ
dysfunction. Physical therapy and opioid use were minimally successful in reducing her pain,
leading her to self-administer vaporized marijuana. Within three months of beginning
self-administration of marijuana, she was able to cease all opioid consumption as well as
dramatically decrease the amount of inpatient and emergency care required. This treatment was
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used alongside continued physical therapy and proved to be highly transformative in this
patient’s case. Marijuana use in hEDS patients is considered to be an effective method of treating
chronic pain with improvements in pain levels and quality of sleep (Jensen et al., 2015).
However, this form of treatment does come with potential side effects. These may include
decreased neuropsychological functioning, decreased alertness, drowsiness, as well as concerns
for its possible effects on brain development. Thus, care must be taken when choosing the proper
treatment for each individual.
One last medication that has been found to reduce pain scores among hEDS patients is
ketamine. This medication is an analgesic medication commonly used in place of opioids in pain
management as well as for general anesthesia. In one case study, ketamine was found to be
effective in reducing an hEDS patient's chronic pain while allowing her to decrease the amount
of opioid medication being consumed, ultimately increasing the quality of life of the patient (Lo
et al., 2016). Ketamine has been found to be effective in treating neuropathic pain as well as pain
due to central sensitization. The mechanism behind ketamine as a pain relief drug is unclear,
though it is hypothesized that it restores the balance between pain inhibition and facilitation. This
balance is thought to be disrupted in both neuropathic pain as well as central sensitization,
known as disinhibition (Kemp et al., 2009), thus this hypothesis would be consistent with prior
explanations for pain mechanisms in hEDS.
According to Rombaut et al. (2011), survey participants with hEDS who have received
treatment including surgery, medication, and physical therapy are more functionally impaired
and present with more complaints of pain than those who have not received these forms of
treatment. This finding indicates the need for a new and more standardized therapeutic approach
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to the clinical treatment of hEDS as well as further research to investigate which therapies prove
to be most effective in this specific population.
Conclusion
Hypermobile Ehlers Danlos Syndrome (hEDS) is a rare, heritable connective tissue
disorder that causes joint instability, chronic pain, fatigue, tissue fragility, and other variable
symptoms. Despite being reported frequently as a symptom of hEDS, chronic pain is a highly
neglected symptom of hEDS as there are no standardized treatment guidelines for physicians to
follow when treating patients. There is a complete lack of education and awareness of this
disease among the healthcare profession and research community alike. The lack of research,
genetic testing, and education tools available for hEDS makes it incredibly difficult for patients
to seek proper care from specialists. As discussed in this review, there is a major diagnostic delay
for hEDS patients, which lessens the quality of life of these individuals significantly. This effect
is seen on an even larger scale when patients seek treatment for chronic pain associated with
their disease, which is often already underestimated in more recognized diseases. Chronic pain in
hEDS is highly under-researched, thus the underlying mechanism of the pain is a topic of debate.
The three hypotheses suggested by researchers to explain the underlying mechanism of
chronic pain in hEDS include musculoskeletal trauma, central sensitization, and small fiber
neuropathy. The research that has been covered in this paper serves as overwhelming evidence
that all suggested mechanisms of pain play a role in the development of chronic pain. The first
pain mechanism of musculoskeletal trauma may be the most obvious. The deficit in structural
integrity resulting from the defective collagen leads to a higher risk of injuries, dislocations, and
subluxations, as well as microtraumas. These injuries then lead to a higher nociceptive activity.
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Central sensitization also leads to higher nociceptive activity as a result of recurring injuries,
sensitizing the central nervous system to nociceptive input. Results of participant studies,
including participants presenting with an increased wind-up ratio, a lower pain/pressure
threshold even in asymptomatic areas, and widespread pain. Finally, small fiber neuropathy is
thought to be present in hEDS due to hyperelasticity and has been proven by skin biopsies,
neuropathy questionnaires, hypoesthesia following heat stimulus. Both central sensitization and
neuropathic pain are thought to be propagated by increased upregulation and disinhibition in the
central nervous systems of hEDS patients. This mechanism can be supported by research that
found that the central nervous systems of hEDS participants were unable to properly respond to a
painful, repeated “conditioning” stimulus by lowering the perceived pain intensity; instead, the
participant perceived the same amount of pain throughout. Since this mechanism is involved in
the propagation in both pain pathologies, they likely coexist in the central nervous systems of
hEDS patients just as studies suggest.
The therapies found to be most efficacious based on clinical and self-reported research
include target physical therapy programs, myofascial trigger point injections, opioids, marijuana,
and ketamine. Surgery is also commonly suggested for the treatment of this disorder but is
beneficial in limited circumstances. Physical therapy is apparent to be the most helpful of all
available treatments as it was found in several studies to decrease the pain scores of participants
dramatically, and it offers the benefit of a highly individualized treatment program. Myofascial
trigger point injections have limited research to support their efficacy, though it appears in
literature to be a non-invasive, simple, and long-lasting treatment. More research must be
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conducted regarding effective pain medication for hEDS as much of the data regarding their
efficacy is self-reported and their side effects were not often considered in the literature.
Although there is literature that offers explanations for the debilitating chronic pain
experienced by hEDS patients, there is still much research to be done to determine the pain
pathology of hEDS as fact. If there is more than one pain mechanism at hand as the literature
suggests, then pain management must be based on the overruling mechanism present in the
patient. A standardized protocol for the recognition, diagnosis, and treatment of hEDS must be
created, as well as educative tools, such as brochures, for both patients and physicians to be
available in the clinical setting. There is also a need for more research to be done to investigate
new and effective treatment plans for pain management in hEDS. In the past two decades, the
research and medical community have given much more recognition to this complex and rare
group of heritable disorders. However, there is still much work to be done to raise awareness for
this disease as the diagnostic delay remains high and the quality of life low. A change in the
diagnosis and treatment of hEDS patients will not be easy, though it is possible with the proper
education and research available to the community and healthcare providers alike.
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